<DOC>
	<DOCNO>NCT00002956</DOCNO>
	<brief_summary>RATIONALE : Donor lymphocytes expose Epstein-Barr virus may able help body kill cancer associate virus . PURPOSE : Phase I trial study effectiveness Epstein-Barr virus-specific T cell derive matched donor organ transplant patient lymphoproliferative disease associate Epstein-Barr virus .</brief_summary>
	<brief_title>Immunotherapy Lymphoproliferative Diseases Associated With Epstein-Barr Virus Patients Who Have Undergone Organ Transplants</brief_title>
	<detailed_description>OBJECTIVES : I . Examine toxic effect allogeneic Epstein-Barr virus ( EBV ) specific cytotoxic T lymphocytes ( CTL ) treatment EBV lymphoproliferative disease ( LPD ) organ transplant recipient . II . Determine level vivo expansion allogeneic CTL period time CTL 's detected blood recipient T cell infusion . OUTLINE : Donors undergo leukapheresis , Epstein-Barr virus ( EBV ) specific cytoxic T lymphocytes cultivate vitro . Patients receive infusion EBV specific cytotoxic T lymphocytes 5 10 minute week 0 , 2 , 4 . Patients stable disease achieve partial remission follow weekly sign disease progression . PROJECTED ACCRUAL : 10 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>Inclusion criterion : Radiographic evidence lymphadenopathy lymphomatous lesion combine clinical sign EpsteinBarr virus lymphoproliferative disease ( EBV LPD ) , fever lymphadenopathy follow organ transplant Persistent , progressive , unresponsive disease despite decreased immunosuppression , chemotherapy , radiation therapy EBV LPD must host origin At least 4 week Patients serologically hepatitis B C positive may receive cytotoxic T lymphocytes ( CTL ) donor serologically positive virus Must HLA identical HLA haploidentical donor Exclusion hepatic dysfunction SGOT/SGPT le 2.5 time upper limit normal ( unless liver metastasis present ) Bilirubin le 2.0 mg/dL renal dysfunction Creatinine clearance great 50 mL/min cardiac dysfunction neurologic dysfunction pulmonary dysfunction patient develop EBV LPD donor origin lymphoma HIV1 positive Not capable undergoing leukapheresis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>